Hi folks. This was a relatively quiet week without the approval of any new molecular entities. Here is my recap of the top regulatory news stories this week: The FDA agreed to expand the label for AstraZeneca’s immunotherapy Imfinzi (durvalumab) to reduce the risk of non-small-cell lung cancer progression in patients with stage III[…]